Ekso Bionics Q3 2025 Financial Results

Ekso Bionics Holdings, Inc. reported its financial results for the third quarter of 2025, showing a 2% year-over-year revenue increase to $4.2 million and a significant sequential rebound of 105% from the previous quarter. The company achieved a gross margin of 60.3%, up from 53.5% in the same period last year, driven by higher margin Enterprise Health sales and lower device costs. Net loss improved by 31% year-over-year to $1.4 million. The company also announced the launch of eksoUniversity and is exploring strategic transactions, including potential acquisitions or sales of business lines, which may require stockholder approval.